Chiara Ambrogio BS, PhD

Chiara Ambrogio, PhD, (Chiara_Ambrogio@dfci.harvard.edu) investigates the KRAS signaling pathway in both normal and pathophysiologic states, to aid in developing new therapeutic strategies. Using isogenic cell lines of mouse and human origin expressing different KRAS oncogenic mutations, she characterizes novel compounds for the direct inhibition of KRAS in lung cancer.